AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 15240597
Drug: Nutropin Depot
RxNorm normalized name: Nutropin Depot
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutropin Depot 0.75 mg/kg once per month
Trial: 15240597
Drug: Nutropin Depot
RxNorm normalized name: Nutropin Depot
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutropin Depot 0.75 mg/kg twice per month
Trial: 15240597
Drug: Nutropin Depot
RxNorm normalized name: Nutropin Depot
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutropin Depot 1.5 mg/kg once per month
Trial: 15240597
Drug: Nutropin Depot
RxNorm normalized name: Nutropin Depot
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutropin Depot (all dosing regimens)
Trial: 9722130
Drug: Tamoxifen 20
RxNorm normalized name: tamoxifen 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen 20 mg/day for 10 consecutive days starting on the 13th day of the menstrual cycle
Trial: 8002320
Drug: Fluoxetine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (20 mg, increased to 40 mg based on response)
Trial: 18835927
Drug: Placebo (identical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (identical to fluoxetine)
Trial: 3404502
Drug: Dentist-administered ultrasound
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dentist-administered ultrasound
Trial: 27560168
Drug: pioglitazone (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pioglitazone (30 mg for 4 weeks, then 45 mg for 8 weeks)
Trial: 20598974
Drug: Elinogrel (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elinogrel (intravenous and oral formulations)
Trial: 11136293
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg microencapsulated octreotide acetate intramuscularly
Trial: 8799516
Drug: Intravenous phylloquinone
RxNorm normalized name: Phylloquinone
DrugBank: Phylloquinone (DB01022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous phylloquinone (vitamin K1) mixed micelles formulation (Konakion MM)
Trial: 8799516
Drug: Intramuscular phylloquinone
RxNorm normalized name: Phylloquinone
DrugBank: Phylloquinone (DB01022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular phylloquinone (vitamin K1) mixed micelles formulation (Konakion MM)
Trial: 1629383
Drug: Alprazolam (average
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprazolam (average maximum dosage 2.2 mg)
Trial: 1629383
Drug: Imipramine (average
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine (average maximum dosage 97.5 mg)
Trial: 6483520
Drug: Slow-release theophylline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow-release theophylline sprinkle preparation (fasting)
Trial: 6483520
Drug: Slow-release theophylline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow-release theophylline sprinkle preparation (after standardized meal)
Trial: 29537451
Drug: Sarecycline 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sarecycline 1.5 mg/kg
Trial: 29537451
Drug: Sarecycline 3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sarecycline 3.0 mg/kg
Trial: 28139568
Drug: Combined chemoradiotherapy
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined chemoradiotherapy (CRT) with 75 mg/m2 temozolomide (TMZ) followed by 200 mg/m2 TMZ for 5 days every 28 days
Trial: 20054294
Drug: Repaglinide treatment
RxNorm normalized name: Repaglinide
DrugBank: Repaglinide (DB00912)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Repaglinide treatment for 8 weeks
Trial: 20039413
Drug: Rituximab (1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab (1,000 mg) administered on days 1, 15, 168, and 182
Trial: 10894282
Drug: Ritonavir 400
RxNorm normalized name: lopinavir-ritonavir 400 mg-100 mg/5 mL oral liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritonavir 400 mg twice daily plus Indinavir 400 mg twice daily with either Zidovudine/Lamivudine (49%), Stavudine/Lamivudine (38%), or Stavudine/Didanosine (13%)
Trial: 10894282
Drug: Ritonavir 400
RxNorm normalized name: lopinavir-ritonavir 400 mg-100 mg/5 mL oral liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritonavir 400 mg twice daily plus Indinavir 400 mg twice daily
Trial: 10894282
Drug: Ritonavir/Indinavir plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritonavir/Indinavir plus double nucleoside therapy
Trial: 8669994
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment program (daily physiotherapy)
Trial: 8669994
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment program
Trial: 1508127
Drug: Flurbiprofen 300
RxNorm normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flurbiprofen 300 mg/day, orally, starting the day before surgery and continuing for 7 consecutive days
Trial: 6308755
Drug: Pivmecillinam-pivampicillin (PMPA)
RxNorm normalized name: pivampicillin
DrugBank: Pivampicillin (DB01604)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pivmecillinam-pivampicillin (PMPA) 200 + 250 mg b.i.d.
Trial: 6308755
Drug: Pivmecillinam (PM)
DrugBank: Pivmecillinam (DB01605)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pivmecillinam (PM) 400 mg b.i.d.
Trial: 31974708
Drug: Postoperative chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative chemotherapy (POCT)
Trial: 29241383
Drug: 600 µg buccal
RxNorm normalized name: P.G. 600 KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 µg buccal misoprostol
Trial: 29241383
Drug: 1000 mg oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg oral TA plus 600 µg buccal misoprostol
Trial: 16495394
Drug: Alendronate (70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate (70 mg once weekly)
Trial: 15857102
Drug: 1.50 mg/ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.50 mg/ml rhBMP‐2/ACS
Trial: 15857102
Drug: 0.75 mg/ml
RxNorm normalized name: digoxin 0.75 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.75 mg/ml rhBMP‐2/ACS
Trial: 16048928
Drug: Ertapenem (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ertapenem (1 g once a day)
Trial: 12183244
Drug: Ceftriaxone (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone (1 g daily)
Trial: 10968433
Drug: Omapatrilat (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omapatrilat (40 mg daily for 24 weeks)
Trial: 10968433
Drug: Lisinopril (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril (20 mg daily for 24 weeks)
Trial: 1453199
Drug: Progesterone receptor-positive
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Progesterone receptor-positive (PgR+) status and decreasing tumor size
Trial: 4095819
Drug: Glipizide, 1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glipizide, 1.25 mg daily added at breakfast for 10 subjects after 6 months of dietary and exercise treatment
Trial: 4095819
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (18 GI subjects) with no treatment for 5-10 months
Trial: 21711479
Drug: Tadalafil 5
RxNorm normalized name: tadalafil 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tadalafil 5 mg once-a-day
Trial: 24784894
Drug: Tadalafil 10
RxNorm normalized name: tadalafil 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tadalafil 10 mg on demand
Trial: 24784894
Drug: Sildenafil 50
RxNorm normalized name: sildenafil 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil 50 mg on demand
Trial: 22307061
Drug: Concurrent chemoradiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemoradiation (CCRT) with adjuvant chemotherapy (Paclitaxel 135 mg/m² + Cisplatin 75 mg/m²)
Trial: 22307061
Drug: Concurrent chemoradiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemoradiation (CCRT) alone
Trial: 19957087
Drug: PETN 80
RxNorm normalized name: Pentaerythritol tetranitrate
DrugBank: Pentaerythritol tetranitrate (DB06154)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PETN 80 mg t.i.d.
Trial: 12021739
Drug: Naloxone treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone treatment (10 mg)
Trial: 2086017
Drug: Aspirin 20mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 20mg/d
Trial: 2086017
Drug: Diltiazem plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem plus Aspirin
Trial: 31065992
Drug: Oxycodone ARIR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone ARIR 30 mg under fasted conditions
Trial: 31065992
Drug: Oxycodone ARIR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone ARIR 30 mg under fed conditions
Trial: 31065992
Drug: IR oxycodone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IR oxycodone 30 mg under fasted conditions
Trial: 23084077
Drug: Lutein-based oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lutein-based oral supplement
Trial: 23084077
Drug: No supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No supplement (non-treated group)
Trial: 16908788
Drug: Varenicline tartrate
RxNorm normalized name: Varenicline tartrate
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Varenicline tartrate 1.0 mg twice daily
Trial: 16908788
Drug: Varenicline tartrate
RxNorm normalized name: Varenicline tartrate
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Varenicline tartrate 1.0 mg once daily
Trial: 16908788
Drug: Bupropion hydrochloride
RxNorm normalized name: Bupropion Hydrochloride
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupropion hydrochloride 150 mg twice daily
Trial: 11558289
Drug: CEA with
RxNorm normalized name: Radiance Echinacea with Goldenseal Root Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEA with patching (PTFE or vein patch closure)
Trial: 11558289
Drug: Patching using
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patching using PTFE or vein patch closure
Trial: 11558289
Drug: Hemashield patch
RxNorm normalized name: tolnaftate
DrugBank: Tolnaftate (DB00525)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hemashield patch
Trial: 29061382
Drug: Daily meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily meal distribution approach
Trial: 24665971
Drug: 500 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 μg F/g with 1% TMP
Trial: 24665971
Drug: 500 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 μg F/g with 0.25% CaGP
Trial: 24665971
Drug: 1100 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1100 μg F/g
Trial: 20823381
Drug: Achieved on‐treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Achieved on‐treatment systolic BP levels in the first 24 hours
Trial: 18491071
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (daily docosahexaenoic/eicosapentaenoic acid capsules, no other seafood; single-blinded)
Trial: 18491071
Drug: Lean fish
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lean fish (150 g cod, three times/week)
Trial: 18491071
Drug: Fatty fish
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fatty fish (150 g salmon, three times/week)
Trial: 12970007
Drug: Nebulized levalbuterol,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized levalbuterol, 1.25 mg
Trial: 12970007
Drug: Racemic albuterol,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Racemic albuterol, 2.5 mg
Trial: 12970007
Drug: Combined racemic
RxNorm normalized name: EPINEPHRINE,RACEMIC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined racemic albuterol, 2.5 mg, and ipratropium, 0.5 mg
Trial: 8678103
Drug: Cefepime (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefepime (1 g every 12 hours)
Trial: 8678103
Drug: Ceftazidime (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftazidime (1 g every 8 hours)
Trial: 1906097
Drug: Cefixime (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefixime (8 mg/kg daily)
Trial: 1906097
Drug: Amoxicillin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin (40 mg/kg daily)
Trial: 24458078
Drug: Ferumoxytol (1.02
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ferumoxytol (1.02 g, 2 × 510‐mg injections)
Trial: 24458078
Drug: Iron sucrose
RxNorm normalized name: Iron Sucrose
DrugBank: Iron sucrose (DB09146)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron sucrose (1.0 g, administered as slow injection or infusion)
Trial: 10325782
Drug: Terbutaline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbutaline infusion
Trial: 2019314
Drug: 2 or
RxNorm normalized name: CP-2 Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 or 3 mg/kg diazoxide given 2.5 min before laryngoscopy
Trial: 6765414
Drug: Standard amikacin
RxNorm normalized name: Amikacin
DrugBank: Amikacin (DB00479)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Standard amikacin dosing (15 mg/kg per day in four divided doses) with ticarcillin or piperacillin
Trial: 6765414
Drug: Pharmacokinetically adjusted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacokinetically adjusted amikacin dosing (mean dosage of 29.4 mg/kg per day) with ticarcillin or moxalactam
Trial: 6765414
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (previous amikacin-plus-ticarcillin trial with 15 mg/kg per day)
Trial: 25985046
Drug: Double-blinded fluoxetine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-blinded fluoxetine for 8 months
Trial: 25985046
Drug: Pill placebo
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pill placebo for 8 months
Trial: 25985046
Drug: Continuation-phase treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuation-phase treatments (CT, fluoxetine, placebo)
Trial: 24001030
Drug: ECA (Embodied
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ECA (Embodied Conversational Agent)
Trial: 24001030
Drug: ECA (Embodied
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ECA (Embodied Conversational Agent) for participants with adequate health literacy
Trial: 19061808
Drug: Mini-implants for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mini-implants for en-masse retraction (G1)
Trial: 17718288
Drug: Cinnamon cassia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinnamon cassia powder 1.5 g/d
Trial: 9283507
Drug: Cognitive therapy
RxNorm normalized name: cognitive therapy software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive therapy added to group drug counseling
Trial: 9283507
Drug: Supportive-expressive psychodynamic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive-expressive psychodynamic therapy added to group drug counseling
Trial: 9283507
Drug: Individual drug
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individual drug counseling added to group drug counseling
Trial: 11680559
Drug: Group drug
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group drug counseling alone
Trial: 8393895
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg oral d-fenfluramine
Trial: 14636813
Drug: Skinfolds and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Skinfolds and combination of methods
Trial: 11776204
Drug: LHRH‐a (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LHRH‐a (150 micrograms/d, i.m.) plus norethindrone (2.5 mg/d, p.o.)
Trial: 8634919
Drug: Oral hydralazine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral hydralazine (75 mg qid)
Trial: 1631944
Drug: MALG (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MALG (20 mg/kg/day)
Trial: 1631944
Drug: OKT3 (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OKT3 (5 mg/day)
Trial: 24849445
Drug: 20% mannitol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20% mannitol (2 ml/kg, infused for over 20 min)
Trial: 24849445
Drug: 15% hypertonic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15% hypertonic saline (0.42 ml/kg, administered as a bolus via a central venous catheter)
Trial: 20395226
Drug: Atorvastatin +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin + N-acetylcysteine (NAC)
Trial: 20395226
Drug: Atorvastatin +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin + NAC
Trial: 12794414
Drug: Dexamethasone, 1
RxNorm normalized name: Dexamethasone, 1 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone, 1 mg/kg iv (group II, n = 15)
Trial: 28605472
Drug: ACT +
RxNorm normalized name: sodium fluoride Mouthwash [ACT Fluoride Rinse]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACT + primaquine (0.25 mg/kg)
Trial: 10912897
Drug: salbutamol (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: salbutamol (4 mg)
Trial: 1330880
Drug: Azithromycin 1000
RxNorm normalized name: azithromycin 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin 1000 mg single dose
Trial: 6695766
Drug: Prazosin added
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prazosin added to propranolol (reduced to 120 mg/day)
Trial: 6695766
Drug: Prazosin added
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prazosin added after tapering and discontinuing propranolol
Trial: 23090620
Drug: Capecitabine tablet
RxNorm normalized name: Capecitabine Tablets
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine tablet formulation (500 mg)
Trial: 23090620
Drug: Control formulation
RxNorm normalized name: nut.tx, weight loss-control formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control formulation of capecitabine (500 mg)
Trial: 19120715
Drug: Valsartan 320
RxNorm normalized name: valsartan 320 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan 320 mg/d
Trial: 19120715
Drug: Hydrochlorothiazide (HCTZ)
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (HCTZ) 25 mg/d
Trial: 19120715
Drug: Valsartan/HCTZ 320/25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan/HCTZ 320/25 mg/d
Trial: 16357487
Drug: Growth Hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth Hormone (GH) treatment, n=62
Trial: 16357487
Drug: Baseline food
RxNorm normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline food intake before GH treatment
Trial: 16296712
Drug: Diltiazem (30‐60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (30‐60 mg three times daily)
Trial: 30503386
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg of testosterone cypionate
Trial: 27374668
Drug: Repaglinide (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repaglinide (0.25 or 0.5 mg just before breakfast and dinner twice daily)
Trial: 27374668
Drug: Repaglinide (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repaglinide (0.25 or 0.5 mg just before meals thrice daily)
Trial: 27374668
Drug: Sulfonylurea (continuing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfonylurea (continuing treatment)
Trial: 23483320
Drug: parecoxib sodium
RxNorm normalized name: parecoxib sodium
DrugBank: Parecoxib (DB08439)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: parecoxib sodium (40 mg) intravenously (IV) at the completion of surgery and once every 12 h for a total of 6 times postoperatively
Trial: 23483320
Drug: placebo (normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo (normal saline 2 mL IV at the same time points)
Trial: 19463203
Drug: Fluticasone furoate
RxNorm normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluticasone furoate nasal spray (FFNS), 110 microg
Trial: 17223551
Drug: Serum 25(OH)D
RxNorm normalized name: 1α,25(OH)2D3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum 25(OH)D levels in the second tertile (range 5.5‐66.1 ng/ml)
Trial: 15088221
Drug: Social support
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Social support treatments targeting appropriate use of the health care system
Trial: 12195181
Drug: Pelvic floor
RxNorm normalized name: Tenscare Kegel Toner Pelvic Floor Trainer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pelvic floor exercises and biofeedback treatment
Trial: 2406169
Drug: Home-visiting system
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Home-visiting system with one or two weekly visits by domiciliary midwives
Trial: 396653
Drug: Pirenzepine (PRZ)
RxNorm normalized name: pirenzepine
DrugBank: Pirenzepine (DB00670)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirenzepine (PRZ) 75 mg/day for 1 week followed by 50 mg/day for 3 weeks
Trial: 396653
Drug: Pirenzepine (PRZ)
RxNorm normalized name: pirenzepine
DrugBank: Pirenzepine (DB00670)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirenzepine (PRZ) 100 mg/day for 4 weeks
Trial: 396653
Drug: Carbenoxolone (CB)
RxNorm normalized name: carbenoxolone
DrugBank: Carbenoxolone (DB02329)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbenoxolone (CB) 300 mg/day for 1 week followed by 200 mg/day for 3 weeks
Trial: 23053618
Drug: Immediate CAMP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate CAMP treatment (n = 15)
Trial: 23053618
Drug: Waitlist (delayed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Waitlist (delayed treatment; n = 14)